EBS
Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.23
+3.00% today
Updated 2026-04-30
Market cap
$414.70M
P/E ratio
8.63
P/S ratio
0.56x
EPS (TTM)
$0.93
Dividend yield
—
52W range
$5 – $14
Volume
0.9M
Emergent Biosolutions Inc (EBS) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $100.33M | $238.25M | $273.51M | $290.79M | $344.69M | $500.32M | $546.86M | $564.23M | $626.63M | $945.26M | $1.04B | $970.11M | $1.07B | $2.23B | $2.33B | $2.88B | $2.96B | $3.17B | $1.82B | $1.39B |
| Cash & equivalents | $36.29M | $76.42M | $105.73M | $91.47M | $102.92M | $169.02M | $143.90M | $141.67M | $179.34M | $280.50M | $312.80M | $271.51M | $178.29M | $112.20M | $168.00M | $621.30M | $576.30M | $642.60M | $111.70M | $99.50M |
| Current assets | $59.12M | $147.34M | $144.31M | $152.68M | $193.81M | $243.49M | $254.42M | $263.35M | $273.12M | $432.18M | $538.61M | $510.22M | $485.39M | $620.80M | $686.20M | $1.20B | $1.27B | $1.21B | $679.50M | $598.70M |
| Total liabilities | $40.59M | $99.78M | $102.35M | $91.44M | $100.87M | $126.76M | $130.14M | $122.10M | $137.47M | $392.06M | $383.57M | $373.91M | $157.86M | $1.22B | $1.24B | $1.44B | $1.35B | $1.78B | $1.17B | $906.90M |
| Current liabilities | $30.09M | $64.35M | $55.66M | $54.02M | $54.70M | $75.72M | $71.05M | $61.91M | $56.65M | $92.94M | $99.61M | $105.86M | $100.07M | $200.40M | $216.30M | $384.50M | $374.00M | $1.23B | $651.30M | $162.40M |
| Long-term debt | $10.50M | $31.37M | $42.59M | $35.94M | $44.93M | $30.24M | $54.09M | $58.30M | $62.00M | $251.00M | $253.00M | $248.09M | $13.46M | $784.50M | $798.40M | $841.00M | $809.40M | $448.50M | $446.50M | $663.70M |
| Shareholder equity | $59.74M | $138.47M | $171.16M | $199.35M | $241.20M | $369.46M | $414.25M | $441.36M | $489.62M | $553.20M | $660.02M | $596.21M | $912.35M | $1.01B | $1.09B | $1.45B | $1.61B | $1.38B | $649.30M | $482.80M |
| Retained earnings | $25.40M | $48.00M | $70.33M | $91.01M | $122.15M | $173.85M | $196.87M | $220.39M | $251.53M | $288.27M | $351.14M | $254.48M | $337.07M | $367.30M | $421.80M | $726.90M | $950.30M | $734.00M | $-21.80M | $-212.40M |
| Accounts receivable | $3.29M | $44.20M | $18.82M | $24.86M | $67.45M | $48.05M | $83.66M | $96.04M | $66.24M | $60.19M | $127.34M | $148.47M | $146.09M | $262.50M | $275.30M | $230.90M | $278.90M | $158.40M | $191.00M | $154.50M |
| Inventory | $16.44M | $24.72M | $16.90M | $19.73M | $13.52M | $12.72M | $14.66M | $15.16M | $14.64M | $65.67M | $76.94M | $74.00M | $142.81M | $205.80M | $222.50M | $307.00M | $344.50M | $351.80M | $328.90M | $311.70M |
| Goodwill | — | — | — | — | — | $5.03M | $5.50M | $5.50M | $13.95M | $41.98M | $54.90M | $41.00M | $49.13M | $259.70M | $266.60M | $266.70M | $224.90M | $218.20M | $218.20M | — |